The SCN8A encephalopathy mutation p.Ile1327Val displays elevated sensitivity to the anticonvulsant phenytoin

Epilepsia

Volumn 57, Issue 9, 2016, Pages 1458-1466

  Barker, Bryan S ^a   Ottolini, Matteo ^a   Wagnon, Jacy L ^b   Hollander, Rachel M ^b   Meisler, Miriam H ^b   Patel, Manoj K ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anticonvulsant drugs; Epileptic encephalopathy; Phenytoin; SCN8A; Sodium channels

Indexed keywords

COMPLEMENTARY DNA; PHENYTOIN; SODIUM CHANNEL NAV1.6;

ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; DRUG SENSITIVITY; EPILEPSY; GAIN OF FUNCTION MUTATION; HYPERPOLARIZATION; PRIORITY JOURNAL; SEIZURE; SITE DIRECTED MUTAGENESIS; TREATMENT RESPONSE;

EID: 84985993985     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13461     Document Type: Article

References (27)

1. Cooper DC, Chung S, Spruston N. Output-mode transitions are controlled by prolonged inactivation of sodium channels in pyramidal neurons of subiculum. PLoS Biol 2005;3:e175.
2. Vreugdenhil M, Hoogland G, van Veelen CW, et al. Persistent sodium current in subicular neurons isolated from patients with temporal lobe epilepsy. Eur J Neurosci 2004;19:2769–2778.
3. Wagnon JL, Meisler MH. Recurrent and non-recurrent mutations of SCN8A in epileptic encephalopathy. Front Neurol 2015;6:104.
4. Blumenfeld H, Lampert A, Klein JP, et al. Role of hippocampal sodium channel Nav1.6 in kindling epileptogenesis. Epilepsia 2009;50:44–55.
5. Hargus NJ, Merrick EC, Nigam A, et al. Temporal lobe epilepsy induces intrinsic alterations in Na channel gating in layer II medial entorhinal cortex neurons. Neurobiol Dis 2011;41:361–376.
6. Hu W, Tian C, Li T, et al. Distinct contributions of Na(v)1.6 and Na(v)1.2 in action potential initiation and backpropagation. Nat Neurosci 2009;12:996–1002.
7. Boiko T, Van Wart A, Caldwell JH, et al. Functional specialization of the axon initial segment by isoform-specific sodium channel targeting. J Neurosci 2003;23:2306–2313.
8. Veeramah KR, O'Brien JE, Meisler MH, et al. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet 2012;90:502–510.
9. Blanchard MG, Willemsen MH, Walker JB, et al. De novo gain-of-function and loss-of-function mutations of SCN8A in patients with intellectual disabilities and epilepsy. J Med Genet 2015;52:330–337.
10. Estacion M, O'Brien JE, Conravey A, et al. A novel de novo mutation of SCN8A (Nav1.6) with enhanced channel activation in a child with epileptic encephalopathy. Neurobiol Dis 2014;69:117–123.
11. Wagnon JL, Korn MJ, Parent R, et al. Convulsive seizures and SUDEP in a mouse model of SCN8A epileptic encephalopathy. Hum Mol Genet 2015;24:506–515.
12. Boerma RS, Braun KP, van de Broek MPH, et al. Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach. Neurotherapeutics 2016;13:192–197.
13. Vaher U, Nõukas M, Nikopensius T, et al. De novo SCN8A mutation identified by whole-exome sequencing in a boy with neonatal epileptic encephalopathy, multiple congenital anomalies, and movement disorders. J Child Neurol 2014;29:202–206.
14. Herzog RI, Cummins TR, Ghassemi F, et al. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J Physiol 2003;551:741–750.
15. Wagnon JL, Barker BS, Hounshell JA, et al. Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy. Ann Clin Transl Neurol 2015;3:114–23; doi: 10.1002/acn3.276.
16. Remy S, Urban BW, Elger CE, et al. Anticonvulsant pharmacology of voltage-gated Na+ channels in hippocampal neurons of control and chronically epileptic rats. Eur J Neurosci 2003;17:2648–2658.
17. Kuo CC, Bean BP. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. Mol Pharmacol 1994;46:716–725.
18. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553–564.
19. Singh R, Jayapal S, Goyal S, et al. Early-onset movement disorder and epileptic encephalopathy due to de novo dominant SCN8A mutation. Seizure 2015;26:69–71.
20. Smith MR, Goldin AL. Interaction between the sodium channel inactivation linker and domain III S4-S5. Biophys J 1997;73:1885–1895.
21. Ellerkmann RK, Remy S, Chen J, et al. Molecular and functional changes in voltage-dependent Na(+) channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neuroscience 2003;119:323–333.
22. Ketelaars SO, Gorter JA, van Vliet EA, et al. Sodium currents in isolated rat CA1 pyramidal and dentate granule neurones in the post-status epilepticus model of epilepsy. Neuroscience 2001;105:109–120.
23. Twombly DA, Yoshii M, Narahashi T. Mechanisms of calcium channel block by phenytoin. J Pharmacol Exp Ther 1988;246:189–195.
24. Lenkowski PW, Batts TW, Smith MD, et al. A pharmacophore derived phenytoin analogue with increased affinity for slow inactivated sodium channels exhibits a desired anticonvulsant profile. Neuropharmacology 2007;52:1044–1054.
25. Macdonald RL, Kelly KM. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs. Epilepsia 1994;35(Suppl. 4):S41–S50.
26. Meisler MH, Helman G, Hammer MF, Fureman BE, Gaillard WD, Goldin AL, Hirose S, Ishii A, Kroner BL, Lossin C, Mefford HC, Parent JM, Patel M, Schreiber J, Stewart R, Whittemore V, Wilcox K, Wagnon JL, Pearl PL, Vanderver A, Scheffer IE (2016) SCN8A Encephalopathy: Research Progress and Prospects. Epilepsia, June 8 Epub ahead of print.
27. Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 1977;69:497–515.